Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank You, this is great news.... Falls around the corner.
Hey post this on Kaly board please or post the link. Thanks, everything helps.
Lol, I said this, that they will push it through. This is great news...
So your saying the artical was written by the GNBT team, stating progress and moving forward statements. Now your saying nothing they posted through a promoter is fluff cause they used that particular promoter? Lol, thought that's what promoters do, even the so to say good ones, whatever that means. Yeah right, any PR, statements from a company u are trying to pick up cheap shares from falls into your so to say "fluff news promoters". Now how can you prove this promoter and or companies news is fluff? You can't so end of conversation. To me, YFOS. Stay safe buddy.
You must be talking about yourself. Me I didn't invest in pjet. That's your problem, I'm sure there's many people that didn't invest there. I'm invested in USCH. There's a diffrence, if you haven't notice, my advice to you, be a little more astringent in you DD.
Guess news/PRs are fluff from any source than, iS that what your saying? Lmfao. Good one...lol
Please verify the contract, must have missed that one. If they had a contract with Coke, do you really think their pps would be where its at... Again Lmfao... My goodness.
There goes your fluff statement right out the window..lol
By the way, PURA didn't do the PR, GNBT did. Lmfao
That have a distribution network? Wow... Looking at a buyout of USCH? Wow, wow. Can't wait for the next results comming from them this would be huge if they pick up USCH.
NuGenerex Distribution Solutions. The agreement with Puration is an initial step in the development of a larger and more comprehensive strategy where Generex is exploring the possible acquisition of US Cannabis Health, a joint venture company that includes Puration’s participation with other innovators in the pursuit of developing new cannabinoid therapies.
Anybody remember this? A million bottle contract. Guess who’s providing the hemp, and extraction. Remember USCH, who the partners are? NOUV, KALY and PURA, ring a bell?
Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies
PRESS RELEASE Businesswire
Nov. 26, 2018, 09:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) today announced an agreement with Puration, Inc. (USOTC: PURA) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water. The CBD used in the NuGenerex CBD HydroHealth product line will be exclusively derived from industrial hemp using a patented extraction process that yields ultra-purified and characterized CBD formulations. Generex plans to build on Puration’s track record in developing and marketing a successful line of CBD infused drinks in the sports nutrition market. Under the terms of the agreement, Puration will refine its patented extraction process to develop proprietary CBD formulations for NuGenerex CBD HydroHealth Water, which will be sold as therapeutic supplements for health maintenance in conditions in which CBD therapy has shown promise including, arthritis, epilepsy, chronic pain, generalized anxiety, diabetes, and cancer. The FDA has already approved a formulation of CBD called Epidiolex® for childhood epilepsy. Generex CBD HydroHealth Water is the first of a planned product line of NuGenerex CBD therapies, from alkaline water formulations to salves and creams for pain management that will be marketed through our wholly-owned subsidiary NuGenerex Distribution Solutions. The agreement with Puration is an initial step in the development of a larger and more comprehensive strategy where Generex is exploring the possible acquisition of US Cannabis Health, a joint venture company that includes Puration’s participation with other innovators in the pursuit of developing new cannabinoid therapies.
"Subject to testing and corresponding regulatory approvals, we’re targeting a million-bottle launch of Generex CBD HydroHealth Water in 2019,” said Joseph Moscato, Generex President & Chief Executive Officer. "Given the network of pharmacies Generex owns itself, we are confident we can achieve if not exceed our million-bottle launch target. Puration’s experience and the caliber of Puration’s underlying extraction technology combined with the recently updated production facilities of Puration’s co-packer, are instrumental in Generex’s plan to rapidly launch NuGenerex CBD HydroHealth Water.”
"We are especially excited about Puration’s patented extraction technology that enables us to explicitly define and characterize the CBD and cannabinoid content of hemp extracts to develop proprietary, patented formulations for NuGenerex,” said Jason Terrell, MD, Chief Medical and Scientific Officer of Generex. "Through NuGenerex Distribution Solutions, we have the consumer connections, technology, and HIPAA compliant systems that will enable us to compile real world evidence on the safety and effectiveness of our NuGenerex CBD products for health maintenance in a variety of chronic conditions.”
"In anticipation of the agreement announced today with Generex, we have already been working on new CBD extracts to support Generex’s therapeutic objectives,” said Brian Shibley, CEO of Puration, Inc. "With our US Cannabis Health partners, we are confident in the potential of the new extracts to meet and exceed Generex’s expectations. We are honored to be engaged by a company the caliber of Generex on this exciting project.”
About Generex Biotechnology Corporation
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, Health devices, and pharmaceutical development.
The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.
On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care.
Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary buccal administration of insulin.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005204/en/
Anybody remember this? A million bottle contract. Guess who’s providing the hemp, and extraction. Remember USCH, who the partners are? NOUV, KALY and PURA, ring a bell?
Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies
PRESS RELEASE Businesswire
Nov. 26, 2018, 09:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) today announced an agreement with Puration, Inc. (USOTC: PURA) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water. The CBD used in the NuGenerex CBD HydroHealth product line will be exclusively derived from industrial hemp using a patented extraction process that yields ultra-purified and characterized CBD formulations. Generex plans to build on Puration’s track record in developing and marketing a successful line of CBD infused drinks in the sports nutrition market. Under the terms of the agreement, Puration will refine its patented extraction process to develop proprietary CBD formulations for NuGenerex CBD HydroHealth Water, which will be sold as therapeutic supplements for health maintenance in conditions in which CBD therapy has shown promise including, arthritis, epilepsy, chronic pain, generalized anxiety, diabetes, and cancer. The FDA has already approved a formulation of CBD called Epidiolex® for childhood epilepsy. Generex CBD HydroHealth Water is the first of a planned product line of NuGenerex CBD therapies, from alkaline water formulations to salves and creams for pain management that will be marketed through our wholly-owned subsidiary NuGenerex Distribution Solutions. The agreement with Puration is an initial step in the development of a larger and more comprehensive strategy where Generex is exploring the possible acquisition of US Cannabis Health, a joint venture company that includes Puration’s participation with other innovators in the pursuit of developing new cannabinoid therapies.
"Subject to testing and corresponding regulatory approvals, we’re targeting a million-bottle launch of Generex CBD HydroHealth Water in 2019,” said Joseph Moscato, Generex President & Chief Executive Officer. "Given the network of pharmacies Generex owns itself, we are confident we can achieve if not exceed our million-bottle launch target. Puration’s experience and the caliber of Puration’s underlying extraction technology combined with the recently updated production facilities of Puration’s co-packer, are instrumental in Generex’s plan to rapidly launch NuGenerex CBD HydroHealth Water.”
"We are especially excited about Puration’s patented extraction technology that enables us to explicitly define and characterize the CBD and cannabinoid content of hemp extracts to develop proprietary, patented formulations for NuGenerex,” said Jason Terrell, MD, Chief Medical and Scientific Officer of Generex. "Through NuGenerex Distribution Solutions, we have the consumer connections, technology, and HIPAA compliant systems that will enable us to compile real world evidence on the safety and effectiveness of our NuGenerex CBD products for health maintenance in a variety of chronic conditions.”
"In anticipation of the agreement announced today with Generex, we have already been working on new CBD extracts to support Generex’s therapeutic objectives,” said Brian Shibley, CEO of Puration, Inc. "With our US Cannabis Health partners, we are confident in the potential of the new extracts to meet and exceed Generex’s expectations. We are honored to be engaged by a company the caliber of Generex on this exciting project.”
About Generex Biotechnology Corporation
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, Health devices, and pharmaceutical development.
The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.
On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care.
Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary buccal administration of insulin.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005204/en/
I traded this with etrade and TD. Don't know what your difficulties are. I have no problem trading Kaly.
Anybody remember this? A million bottle contract. Guess who’s providing the hemp, and extraction. Remember USCH, who the partners are? NOUV, KALY and PURA, ring a bell?
Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies
PRESS RELEASE Businesswire
Nov. 26, 2018, 09:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) today announced an agreement with Puration, Inc. (USOTC: PURA) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water. The CBD used in the NuGenerex CBD HydroHealth product line will be exclusively derived from industrial hemp using a patented extraction process that yields ultra-purified and characterized CBD formulations. Generex plans to build on Puration’s track record in developing and marketing a successful line of CBD infused drinks in the sports nutrition market. Under the terms of the agreement, Puration will refine its patented extraction process to develop proprietary CBD formulations for NuGenerex CBD HydroHealth Water, which will be sold as therapeutic supplements for health maintenance in conditions in which CBD therapy has shown promise including, arthritis, epilepsy, chronic pain, generalized anxiety, diabetes, and cancer. The FDA has already approved a formulation of CBD called Epidiolex® for childhood epilepsy. Generex CBD HydroHealth Water is the first of a planned product line of NuGenerex CBD therapies, from alkaline water formulations to salves and creams for pain management that will be marketed through our wholly-owned subsidiary NuGenerex Distribution Solutions. The agreement with Puration is an initial step in the development of a larger and more comprehensive strategy where Generex is exploring the possible acquisition of US Cannabis Health, a joint venture company that includes Puration’s participation with other innovators in the pursuit of developing new cannabinoid therapies.
"Subject to testing and corresponding regulatory approvals, we’re targeting a million-bottle launch of Generex CBD HydroHealth Water in 2019,” said Joseph Moscato, Generex President & Chief Executive Officer. "Given the network of pharmacies Generex owns itself, we are confident we can achieve if not exceed our million-bottle launch target. Puration’s experience and the caliber of Puration’s underlying extraction technology combined with the recently updated production facilities of Puration’s co-packer, are instrumental in Generex’s plan to rapidly launch NuGenerex CBD HydroHealth Water.”
"We are especially excited about Puration’s patented extraction technology that enables us to explicitly define and characterize the CBD and cannabinoid content of hemp extracts to develop proprietary, patented formulations for NuGenerex,” said Jason Terrell, MD, Chief Medical and Scientific Officer of Generex. "Through NuGenerex Distribution Solutions, we have the consumer connections, technology, and HIPAA compliant systems that will enable us to compile real world evidence on the safety and effectiveness of our NuGenerex CBD products for health maintenance in a variety of chronic conditions.”
"In anticipation of the agreement announced today with Generex, we have already been working on new CBD extracts to support Generex’s therapeutic objectives,” said Brian Shibley, CEO of Puration, Inc. "With our US Cannabis Health partners, we are confident in the potential of the new extracts to meet and exceed Generex’s expectations. We are honored to be engaged by a company the caliber of Generex on this exciting project.”
About Generex Biotechnology Corporation
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, Health devices, and pharmaceutical development.
The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care.
On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care.
Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary buccal administration of insulin.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005204/en/
Best to get in early imo. Specially at theses prices.
They do have a new web site. Updated with current information.
Here we go PR.....
The endorsement of hemp farming in the United States
PURA is taking advantage of the legalization of hemp farming in the United States through the 2018 Farm Act. The company will work alongside Kali-Extracts, which will source CBD from NOUV’s hemp cultivation operation. According to its CEO, Brian Shibley, NOUV will soon plant hemp on 100 acres of land already irrigated. The partnership between Kali Inc. (OTCMKTS: KALY) and NOUV will help in scaling up operations on the land.
“NOUV already has staff and operations in place with an extensive 25 greenhouse traditional nursery operation generating revenue and paving the way forward future cannabis cultivation,” says Shibley.
Your right planting has not taken place "yet". Didn't say it did, but I know your comprehension status... Hemp is legal, CBD is legal, were waiting on regulations and Texas is pushing the process, read the artical a couple times, I'm sure you will pickup on what it says. Kaly and NOUV is moving forward and are prepared to move as soon as the get go gets going. Now that's what I said and it was based off the companies latest PRs. Hope you understand now instead of throwing out your specutive thoughts on what I stated...lol its all good. Go Kaly, Go NOUV, Go PURA. Now you go speculate some more. It would help you if you posted citations to your comments, just saying, if you can find any. Glty....
PROCESS MANAGEMENT
KALY and NOUV Pull Trigger on Launching Texas CBD Extraction Lab After Texas Governor Legalizes Hemp and CBD
WERE ON THE MOVE, GREAT THINGS HAPPENING AND MOVING FORWARD.
VERY OLD BS CEs DONT MEAN SQUAT. THEY WILL BE ELIMINATED WHEN THE COMPANY FEELS FIT TOO. A MINOR INFRACTION, EASILY TAKEN CARE OF.
Spike it up, its all good. Texas is legal, NOUV hemp in process, Kaly based on NOUV acres ready for exstraction. Bing, Bing, Bing, setup up and ready to take the raines in the CBD world and future pot extravaganzas. Boom here we go, its all there.
Turn up the Volume...
Dallas, TX -- July 9, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a second hemp derived CBD extraction contract worth $10 million in annual revenue. KALY has previously announced a contract with a New York State Licensed Hemp Cultivation Operation anticipated to generate an estimated $5 million in revenue for KALY. Management has set a 2019 $20 million CBD extraction target. The contract announced today is with Nouveau, Inc. (USOTC: NOUV) (“NOUV”). NOUV has just announced a 100 acre hemp cultivation operation.
Giddyup little doggies. Tick,Tick,Tick, Bavabooom
PURA Management Issues Update On $1.2 Million Stock Dividend From $10 Million Hemp Cultivation Operation
Source: InvestorsHub NewsWire
PURA Management Issues Update On $1.2 Million Stock Dividend From $10 Million Hemp Cultivation Operation
Dallas, TX -- July 9, 2019 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (”PURA”) and Nouveau (USOTC: NOUV) (“NOUV”) management today published an online update on NOUV’s hemp cultivation operation established to generate $10 million in annual revenue and issue a $1.2 million stock dividend to PURA shareholders. PURA on its own has targeted $4 million in revenue from the sales of a variety of cannabis infused beverages in addition to generating additional shareholder value from the NOUV stock dividend. The update published today provides the latest updates on PURA’s strategic overview presentation published on May 30th, 2019. The narrative of the presentation is included in its entirety below and on the company’s website.
PURA and NOUV Management Update
?
PURA and NOUV today published the latest progress toward the acceleration of the NOUV stock dividend to be issued to PURA shareholders in conjunction with PURA’s cannabis cultivation operation.
In October last year, PURA spun off its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note issued by NOUV to PURA. The spinoff deal included a commitment that the note would be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. The prerequisites to issuing the dividend were for NOUV to bring its delinquent financial disclosures current and then execute a 1: 400 reverse spilt to support a 1 for 5 dividend distribution of NOUV common stock to PURA shareholders. The delinquent NOUV financial statements were updated and published yesterday, July 8th, 2019.
Management speculates that scrutiny on penny stocks market-wide has resulted in increased bureaucracy that has in turn resulted in a backlog of disclosure procedures through historically customary channels. Accordingly, NOUV and PURA have devised a plan to work through the prevailing penny market environment.
NOUV has launched its own disclosure site at www.NOUV-INFO.com. The site has been designed for NOUV to be able to publish its own financial statements making them easily accessible to the public without otherwise making shareholders suffer the current bureaucratic delays resulting from what we speculate as increased scrutiny on penny stocks market-wide. The www.NOUV-INFO.com site currently has all NOUV’s historical disclosures in addition to relative market and capital structure information, news and management information, and an NOUV stock quotation. As mentioned above, the delinquent filings have now been updated an publish.
To further work around what has turned out to be the protracted time required to execute a NOUV reverse stock split, NOUV and PURA have alternatively initiated the declaration of a preferred convertible NOUV stock that is intended for immediate distribution to NOUV shareholders. The preferred stock is to be exchanged for the $1.2 million note. Specifically, the plan is for there to be 120 million preferred shares at a value of $0.01 each totaling the $1.2 million. The preferred shares will bear convertible rights to be exchanged for common stock. Once declared and established, NOUV plans to promptly issue the preferred shares to PURA shareholders in a ratio of 1 NOUV preferred share for every 5 PURA shares held.
NOUV $10 Million Hemp Cultivation Revenue Target
The NOUV operations are making great strides. The company has existing conventional nursery operations and transitional cannabis cultivation operations. In addition to the existing conventional nursery operations, NOUV has 100 acers set aside for commercial hemp cultivation. Market estimates anticipate hemp cultivation for CBD extraction to generate over $100,000 per acre. Accordingly, NOUV is targeting $10 million in annual revenue to be generated from the commercial hemp cultivation.
Texas Hemp Rush
The upcoming dividend issuance is more timely than ever now with the recent legalization of hemp farming in Texas pursuant to the Federal legalization of farming under the 2018 Farm Act. Similar to Village Farms in West Texas, a major tomato farming outfit the produces for H-E-B, Tom Albertsons and Walmart, NOUV is expanding its conventional Texas based nursery operation into a major hemp farming operation. PURA shareholders are set to profit from the Texas Hemp Rush as NOUV issues common stock to PURA shareholders in the upcoming dividend issuance.
PURA Speculative Buy Recommendation and $0.25 PPS Target w/Potential to $0.35
Goldman Small Cap Research recently released a new research report recommending PURA as a Speculative BUY with a $0.25 PPS Target. Goldman Small Cap Research further reports that the shares of PURA “have the potential to reach the $0.35 mark.” The report highlights PURA’s growing EVERx CBD Sports Water sales and the coming introduction of new beverages as well as the potential for the company to exceed its 2019 sales targets through the pending doubling of its production capacity and through planned acquisitions. The report further details recent updates intended to accelerate the issue of Nouveau (USOTC: NOUV) stock to PURA shareholders in a dividend distribution. Notably, the report points to the capacity and quality improvements enabled by the addition of a new team member with exceptional beverage industry professional experience.
See the NOUV alternative disclosure website at www.NOUV-INFO.com
See the NOUV Research Analyst Report and Independent Fairness Opinion, at www.NOUV-INFO.com/research
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
https://www.dallasobserver.com/news/texas-legalizes-hemp-11685229
NOUV/KALY/PURA, ready cocked and loaded.
Kaly/NOUV, tick, tick, tick. BaBooooom
https://www.dallasobserver.com/news/texas-legalizes-hemp-11685229
We should be starting to get updates from NOUV on this imo. Were ready to produce, its in NOUV playing field.
https://www.dallasobserver.com/news/texas-legalizes-hemp-11685229
From the last artical I read, Texas is pushing the Agriculture Decision to push the rules for growing the hemp. CBD is legalized but FDA is setting rules, Texas is also pushing the FDA to get off their asses. Nothing confirmed as far as dates, but I'm sure it's going to be a lot sooner than they say, and will surprise us all. Wouldn't want to miss this news comming out and not being invested here with NOUV. I'm sure NOUV is on top of this being a 100 acre farm which is larger than most, will be the first to jump on it the first the legeslation passes.
Back
YahooFINANCE
PURA Confirms $1.2 Million Dividend and NOUV $10 Million Hemp Cultivation Revenue Target
?
PR NewswireJuly 11, 2019, 11:40 AM EDT
DALLAS, July 11, 2019 /PRNewswire/ -- Puration, Inc. (PURA) ("PURA") and Nouveau (NOUV) ("NOUV") today confirmed a $1.2 millionstock dividend of NOUV stock to PURA shareholders and NOUV's 100 acre hemp farm anticipated to generate $10 million in revenue. NOUV further confirmed it has signed a contract with Kali Extracts (KALY) to extract CBD from NOUV's hemp.
PURA and NOUV management earlier this week published an online update on NOUV's hemp cultivation operation established to generate $10 million in annual revenue and issue a $1.2 million stock dividend to PURA shareholders. The update provides the latest updates on PURA's strategic overview presentationpublished on May 30th, 2019. The narrative of the presentation is included again today in its entirety below and on the company's website.
PURA and NOUV Management Update
SCROLL TO CONTINUE WITH CONTENT
Ad
?
PURA and NOUV today published the latest progress toward the acceleration of the NOUV stock dividend to be issued to PURA shareholders in conjunction with PURA's cannabis cultivation operation.
In October last year, PURA spun off its cannabis cultivation business to NOUV in exchange for a $1.2 million convertible note issued by NOUV to PURA. The spinoff deal included a commitment that the note would be converted to common shares of NOUV and that those converted shares would be distributed in a stock dividend to the shareholders of PURA. The prerequisites to issuing the dividend were for NOUV to bring its delinquent financial disclosures current and then execute a 1: 400 reverse spilt to support a 1 for 5 dividend distribution of NOUV common stock to PURA shareholders. The delinquent NOUV financial statements were updated and published yesterday, July 8th, 2019.
Management speculates that scrutiny on penny stocks market-wide has resulted in increased bureaucracy that has in turn resulted in a backlog of disclosure procedures through historically customary channels. Accordingly, NOUV and PURA have devised a plan to work through the prevailing penny market environment.
NOUV has launched its own disclosure site at www.NOUV-INFO.com. The site has been designed for NOUV to be able to publish its own financial statements making them easily accessible to the public without otherwise making shareholders suffer the current bureaucratic delays resulting from what we speculate as increased scrutiny on penny stocks market-wide. The www.NOUV-INFO.comsite currently has all NOUV's historical disclosures in addition to relative market and capital structure information, news and management information, and an NOUV stock quotation. As mentioned above, the delinquent filings have now been updated an publish.
To further work around what has turned out to be the protracted time required to execute a NOUV reverse stock split, NOUV and PURA have alternatively initiated the declaration of a preferred convertible NOUV stock that is intended for immediate distribution to NOUV shareholders. The preferred stock is to be exchanged for the $1.2 million note. Specifically, the plan is for there to be 120 million preferred shares at a value of $0.01 each totaling the $1.2 million. The preferred shares will bear convertible rights to be exchanged for common stock. Once declared and established, NOUV plans to promptly issue the preferred shares to PURA shareholders in a ratio of 1 NOUV preferred share for every 5 PURA shares held.
NOUV $10 Million Hemp Cultivation Revenue Target
The NOUV operations are making great strides. The company has existing conventional nursery operations and transitional cannabis cultivation operations. In addition to the existing conventional nursery operations, NOUV has 100 acres set aside for commercial hemp cultivation. Market estimates anticipate hemp cultivation for CBD extraction to generate over $100,000 per acre. Accordingly, NOUV is targeting $10 million in annual revenue to be generated from the commercial hemp cultivation.
Texas Hemp Rush
The upcoming dividend issuance is more timely than ever now with the recent legalization of hemp farming in Texas pursuant to the Federal legalization of farming under the 2018 Farm Act. Similar to Village Farms in West Texas, a major tomato farming outfit the produces for H-E-B, Tom Albertsons and Walmart, NOUV is expanding its conventional Texas based nursery operation into a major hemp farming operation. PURA shareholders are set to profit from the Texas Hemp Rush as NOUV issues common stock to PURA shareholders in the upcoming dividend issuance.
PURA Speculative Buy Recommendation and $0.25 PPS Target w/Potential to $0.35
Goldman Small Cap Research recently released a new research report recommending PURA as a Speculative BUY with a $0.25 PPS Target. Goldman Small Cap Research further reports that the shares of PURA "have the potential to reach the $0.35 mark." The report highlights PURA's growing EVERx CBD Sports Water sales and the coming introduction of new beverages as well as the potential for the company to exceed its 2019 sales targets through the pending doubling of its production capacity and through planned acquisitions. The report further details recent updates intended to accelerate the issue of Nouveau (NOUV) stock to PURA shareholders in a dividend distribution. Notably, the report points to the capacity and quality improvements enabled by the addition of a new team member with exceptional beverage industry professional experience.
See the NOUV alternative disclosure website at www.NOUV-INFO.com
See the NOUV Research Analyst Report and Independent Fairness Opinion, at www.NOUV-INFO.com/research
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
?
Cision
View original content:http://www.prnewswire.com/news-releases/pura-confirms-1-2-million-dividend-and-nouv-10-million-hemp-cultivation-revenue-target-300883580.html
Start the conversation
Sign in to post a message.
?
What to Read Next
Lab After Texas Governor Legalizes Hemp and CBD
Dallas, TX -- June 13, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Nouveau (USOTC: NOUV) (“NOUV”) today announced moving forward with a CBD extraction lab the two companies have had in the works now that Texas Governor Greg Abbott signed a new law Monday this week legalizing hemp and hemp-derived products. NOUV has 100 acer’s set aside for hemp cultivation. NOUV currently operates a 25-greenhouse growing operation and in partnership with KALY plans to build an additional state-of-the-art greenhouse for the purpose of developing a proprietary cannabis cultivar. KALY has a U.S. Patented Cannabis Extraction Process. Together NOUV and KALY plan to develop proprietary extractions from proprietary cultivars.
This would really take off if they gave us updates on land preparation for growth, where the licence is to grow, Kaly facility progress, and some pics of the farm and address confirmation. Hope the CEO reads the boards to see this. If they spark news like this, NOUV will take off to .01 and further with updates. They need to keep us more informed with progress. I'm in this for the long run, I really don't care what people on I hub think or say. The 100 acre farm has an address and you can pull old pics up with Google world to see it. That's one of the reasons I'm here, the 100 acres is HUGE compared to other companies growing hemp, plus there's other states and countries NOUV is involved in with other companies like Kaly, PURA and Alyi. This Wil be giant in due time, its a matter of keeping us informed about NOUV alone and some pics on their new web site would do the trick to start off with. I'm here with NOUV and not going anywhere, this play will be the beast, next to Kaly imo.
Wake up nouv. Where's the volume?
Lol, no comparison. Way different beast.
If we get volume here we can break the 5s.
SHES GONNA BLOW. 1000% TO THE CEILING. BOOOOOOOM
KALY 400% to 1000% ROI Potential
KALY has endured excessive short selling with well over 50% of the recent trading volume coming from short sales. FINRA has reported short selling as high as 83% of the total volume. The candlestick pattern today indicates a coming reversal is on the horizon and the short sellers having to cover from excessive short sales could drive the KALY PPS even higher. The company has announced $15 million in CBD Extraction Contracts. KALY reached almost $0.04 high late last year after acquiring the US Patented Cannabis Extraction Process that is currently the center of the company’s growing value. With KALY’s patented cannabis pharmaceutical research now coming to light in combination with the $15 million in CBD extraction contracts, the PPS is positioned to shoot past the recent $0.04 high. With a short squeeze bonus, a $0.10 PPS is not an unreasonable milestone.
10 year old PRs, yeah right. The Verge mafia story continues, but never any solid Proof by wannabes Ihub investigators...lol 10 years ago. Lots has changed from 10 years ago. PURA is on the edge of great things comming. We shall see, but don't jump ship just yet, no proof of anything the downplayed are trying to make you believe. Usally there's a motive to swipe up cheap shares by trying to scare investors out of their shares. Hopefully we heard the last of the BS and their gone like the hey said. Lol who am I kidding the will always be sitting on the fence.
Opened at 5, and room to move up. We can jump on it here today and get this out of the past rut. 6s with news today.
Your right on the money. I haven't budge and don't plan too. I seen this heading north along time ago. Kaly strong.
Funny didn't see that PR.